Title: Overcoming resistance to third-generation epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer
Abstract: In the treatment of non-small cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations, EGFR-tyrosine kinase inhibitor (EGFR-TKI) is a key drug that can prolong the survival of patients.
Publication Year: 2017
Publication Date: 2017-09-18
Language: en
Type: article
Access and Citation
Cited By Count: 2
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot